Skip to content

Latest

No7 introduces Lift & Luminate Day & Night Serum

Next month, Boots plans to extend its No7 skin care line in the United States with Lift & Luminate Day & Night Serum. The company said Wednesday that the two-step system targets the three main signs of aging — uneven skin tone, the appearance of lines and wrinkles, and the loss of

iMedicare grows pharmacy base for Medicare Part D tool

iMedicare, a comparison platform for Medicare prescription drug plans, is now available in 500 pharmacies nationwide. The company said Wednesday that its Medicare decision-making technology helps thousands of seniors enroll in affordable drug benefit plans and health insurance coverage.

Shoppers Drug Mart unveils new beautyBOUTIQUE

Shoppers Drug Mart Corp. has opened the latest iteration of its beautyBOUTIQUE store-within-store concept in Toronto. CEO Domenic Pilla introduces the new beautyBOUTIQUE iat the chain’s Toronto Eaton Centre store.

Endo to purchase Boca Pharmacal

In another example of pharmaceutical industry consolidation, Endo Health Solutions — through its Qualitest subsidiary — is acquiring privately held Boca Pharmacal, a specialty generic drug firm, for $225 million in cash.

RxAlly pharmacy alliance shut down

RxAlly, an alliance of more than 22,000 independent and regional pharmacies and Walgreen Co., has closed. The company, launched in February 2012, ceased operations on Friday, according to a statement on its website.

Akorn to acquire Hi-Tech Pharmacal

Akorn Inc. plans to acquire Hi-Tech Pharmacal Co. for $640 million in a move to expand its eye drug portfolio to oral liquids and ointments. Akorn said Tuesday that the all-cash deal will make it the third-largest U.S.

Advil extends line with film-coated tablets

Pfizer Consumer Healthcare has expanded its Advil pain relief lineup with fast-acting Advil Film Coated tablets. Advil Film Coated comes in tablet and capsule forms and in a premium white box. The company said Monday that the new product marks the U.S.

Amgen to buy Onyx for $10.4 billion

Amgen plans to acquire oncology specialist Onyx Pharmaceuticals Inc. in a deal valued at $10.4 billion overall. Under the acquisition agreement, announced Sunday evening, Amgen will purchase all of the outstanding shares of Onyx at $125 per share in cash. Net of estimated Onyx cash, the purchase